Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
75.54 USD | -3.13% |
|
+3.34% | +143.76% |
10/07 | Goldman Sachs Raises Price Target on Insmed to $102 From $74, Maintains Buy Rating | MT |
09/07 | Guggenheim Adjusts Price Target on Insmed to $95 From $70, Maintains Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+143.76% | 1.22TCr | |
+20.03% | 13TCr | |
+23.61% | 12TCr | |
+22.56% | 2.75TCr | |
-18.07% | 2.09TCr | |
-14.06% | 1.7TCr | |
-14.81% | 1.63TCr | |
+9.78% | 1.46TCr | |
-46.10% | 1.51TCr | |
+52.34% | 1.39TCr |
- Stock Market
- Equities
- INSM Stock
- News Insmed Incorporated
- Transcript : Insmed Incorporated Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 04